Free Daily Headlines :

  • COVID-19
  • Vaccine Info
  • Money
  • Politics
  • Education
  • Health
  • Justice
  • More
    • Environment
    • Economic Development
    • Gaming
    • Investigations
    • Social Services
    • TRANSPORTATION
  • Opinion
    • CT Viewpoints
    • CT Artpoints
DONATE
Reflecting Connecticut’s Reality.
    COVID-19
    Vaccine Info
    Money
    Politics
    Education
    Health
    Justice
    More
    Environment
    Economic Development
    Gaming
    Investigations
    Social Services
    TRANSPORTATION
    Opinion
    CT Viewpoints
    CT Artpoints

LET�S GET SOCIAL

Show your love for great stories and out standing journalism

Westporter Gottlieb to face Senate scrutiny of his bid to head FDA

  • Health
  • by Ana Radelat
  • April 4, 2017
  • View as "Clean Read" "Exit Clean Read"

Gottlieb Twitter feed

Scott Gottlieb

Washington – Sen. Chris Murphy will introduce Scott Gottlieb, a Westport resident and candidate to head the Food and Drug Administration, to fellow members of the Senate panel that’s key to his confirmation – but that won’t keep the nominee from having a bit of a rough ride among Democrats.

At Wednesday’s confirmation hearing by the Senate Health, Education, Labor and Pensions Committee, Murphy is expected to talk about Gottlieb’s career as a doctor – he once practiced at Stamford Hospital – and of his prior experience at the FDA.

Fellow Democrats on the HELP Committee say they will scrutinize possible financial conflicts. The 44-year-old Gottlieb serves on advisory boards for several major pharmaceutical companies. President Donald Trump chose Gottlieb to head the FDA last month

In his recent financial disclosure letter to the Department of Health and Human Services counsel for ethics, Gottlieb disclosed financial relationships with over 25 companies, many of them giants in the biotech and pharmaceutical industries, including GlaxoSmithKline.

In his ethics letter, Gottlieb said he would recuse himself from “particular matters” that involve any of the pharmaceuticals or health care companies he’s been involved with.

That’s not good enough for Michael Carome, a doctor and director of Public Citizen’s Health Research Group, who says FDA commissioners are seldom involved in “particular matters,” including drug approvals, involving pharmaceuticals.

“But he is going to be in on many broad policy decisions that will benefit the bottom line of companies with whom he has had a relationship for years,” Carome said.

As FDA commissioner, Gottlieb would lead an agency that has oversight of more than a fourth of  the U.S. economy, including not just pharmaceuticals but medical devices, food safety, cosmetics and other areas of human and animal health.

His selection has been praised by several GOP senators, including Sen. Lamar Alexander, R-Tenn., the head of the HELP Committee.

“Dr. Gottlieb has impressive qualifications helping American patients as both a physician and in his previous roles at the FDA,” Alexander said.

Even critics like Carome say Gottlieb’s credentials and experience make him well-qualified for the job. Trained at Mount Sinai School of Medicine, he’s been a practicing doctor and a prolific writer and speaker on medical innovations. He also knows the inner workings of the FDA, having served as the agency’s deputy commissioner under President George W. Bush.

“He brings to the table a certain amount of medical knowledge and knowledge about the FDA,” Carome said.

Gottlieb is also a cancer survivor, having been successfully treated for Hodgkin’s lymphoma.

A problem for Carome and others, however, is Gottlieb’s conservative leaning on health care policy.

U.S. Food and Drug Administration

The main entrance of FDA Building 1, which houses the commissioner’s office.

Gottlieb is a venture partner at New Enterprise Associates, where he focuses on health care investment. But he’s also a resident fellow of the American Enterprise Institute and a regular contributor to the Wall Street Journal, Forbes and other publications where he criticized the Affordable Care Act and what he views as excessive federal regulation.

“In so heavily prioritizing one of its obligations — the protection of consumers — the FDA has sometimes subordinated and neglected its other key obligation, which is to guide new medical innovations to market,” Gottlieb wrote in a 2012 issue of National Affairs. “Ultimately, the only way to change the threshold for approval of these sorts of drugs is to change the FDA review culture itself.”

The Pharmaceutical Research and Manufacturers of America, the pharmaceutical industry’s trade association, backs the nomination.

But Rep. Rosa DeLauro, D-3rd District, the top Democrat on a House Appropriations subcommittee with authority over the FDA, said Trump’s choice of Gottlieb “sends a dangerous message that he is committed to rolling back regulations and opening the floodgates to potentially dangerous drugs and medical devices.”

“With Mr. Gottlieb’s nomination, I am extremely concerned that President Trump will use the FDA as his go-to agency for his plan to repeal two existing regulations for every new regulation proposed,” DeLauro said in a statement. “We have these regulations in place to ensure that our nation’s drug supply is safe, effective, and life-saving. Now that Mr. Gottlieb will oversee the FDA, he must remove himself from any pharmaceutical industry ties — of which he has many — and work for the American people, not for the drug and medical device industries.”

If Gottlieb is approved by the Senate, there are concerns among Democrats that he may target “off-label” promotion of certain drugs. During the Obama administration, the FDA issued tighter restrictions on how companies could market drugs for conditions not mentioned on drug labels. Gottlieb has been critical of those restrictions.

Given the GOP majority in the Senate, Gottlieb’s chances for confirmation are good.

“Odds are that he will be confirmed,” said Carome.

Murphy has not taken a position on the nominee. Spokeswoman Laura Maloney said he ”will be thoroughly reviewing his record and his testimony from the hearing.”

But fellow Democrats already have said they oppose the nominee.

Sen. Edward Markey, D-Mass., was one of the first, saying he is concerned a Gottlieb-led FDA will not be vigorous enough in investigating the role drug companies play in the nation’s opioid crisis.

“Dr. Gottlieb has said he wants the FDA approval process to move faster, and that FDA has too high of a standard for safety. I strongly disagree with that,” Markey said during a call with reporters on Tuesday.

Gottlieb’s disclosure statements show that since the beginning of 2016 he has received almost $45,000 in speaking fees from firms involved in the manufacture and distribution of opioids.

Sign up for CT Mirror's free daily news summary.

Free to Read. Not Free to Produce.

The Connecticut Mirror is a nonprofit newsroom. 90% of our revenue comes from people like you. If you value our reporting please consider making a donation. You'll enjoy reading CT Mirror even more knowing you helped make it happen.

YES, I'LL DONATE TODAY

ABOUT THE AUTHOR

Ana Radelat Ana has written about politics and policy in Washington, D.C.. for Gannett, Thompson Reuters and UPI. She was a special correspondent for the Miami Herald, and a regular contributor to The New York TImes, Advertising Age and several other publications. She has also worked in broadcast journalism, for CNN and several local NPR stations. She is a graduate of the University of Maryland School of Journalism.

SEE WHAT READERS SAID

RELATED STORIES
Aid-in-dying bill clears key hurdle with committee passage
by Jenna Carlesso

The bill would let terminally ill patients access medication to end their lives.

Ned Lamont’s year in the shadow of COVID
by Mark Pazniokas

Ned Lamont has been the face, voice, and interpreter of the COVID crisis, mourning deaths, explaining setbacks and cautiously celebrating.

With billions in federal relief on the way to CT, legislators assert their role in deciding how to spend it
by Keith M. Phaneuf and Mark Pazniokas

With an unusual bill, state legislators are reminding Gov. Ned Lamont they have significant role in disbursing federal coronavirus relief.

How does the public option bill differ from Gov. Ned Lamont’s health care plan? Here’s a look at the two proposals.
by Jenna Carlesso

With the rising cost of care a central issue this legislative session, lawmakers and Gov. Ned Lamont’s administration have each moved ahead with their own plans aimed at driving down prices.

Rep. Patricia Billie Miller wins vacant Senate seat
by Mark Pazniokas

Rep. Patricia Billie Miller, D-Stamford, won a special election to the state Senate.

Support Our Work

Show your love for great stories and outstanding journalism.

$
Select One
  • Monthly
  • Yearly
  • Once
Artpoint painter
CT ViewpointsCT Artpoints
Opinion The public health bill no one is talking about, but should be
by Brian Festa

On February 16,  the legislature's Public Health Committee conducted a public hearing on two bills, S.B. 568 and H.B. 6423, both of which would eliminate the religious exemption to mandatory vaccinations for Connecticut schoolchildren.  The hearing was capped at 24 hours, depriving nearly 1,500 members of the public who had registered for the hearing their opportunity to be heard.  The vast majority of those who did testify, and who submitted written testimony, opposed the bill.  The committee is expected to vote on the bill as early as  today. 

Opinion Students need more resources, fewer officers
by Tenille Bonilla

"School resource officer" is just a nice way to say cop. But what students really need is more resource and less officer.

Opinion The Board of Regents’ changes must not shortchange its students or faculty
by Carrie Andreoletti, PhD

As a university professor and a lifespan developmental psychologist, I tend to approach my work from a developmental perspective. This means I aim to foster a lifelong love of learning and to help others find a sense of meaning and purpose, as well as confidence in their ability to reach their goals. My approach to higher education is shaped by my desire to provide the best possible education for my students. This is why the recent Board of Regents’ proposed changes at the four state universities have me worried.

Opinion How to close schooling opportunity gaps created by the pandemic
by Carol Gale

We ask school district leaders to trust your public servants whose daily work life involves assessing student needs and planning or modifying instruction to meet those needs. Listen to their voices, as we have, and allocate precious resources on interventions that will offer increased opportunities for Hartford students to succeed.

Artwork Grand guidance
by Anne:Gogh

In a world of systemic oppression aimed towards those of darker skintones – representation matters. We are more than our equity elusive environments, more than numbers in a prison and much more than victims of societal dispositions. This piece depicts a melanated young man draped in a cape ascending high above multiple forms of oppression. […]

Artwork Shea
by Anthony Valentine

Shea is a story about race and social inequalities that plague America. It is a narrative that prompts the question, “Do you know what it’s like to wake up in new skin?”

Artwork The Declaration of Human Rights
by Andres Chaparro

Through my artwork I strive to create an example of ideas that reflect my desire to raise social consciousness, and cultural awareness. Jazz music is the catalyst to all my work, and plays a major influence in each piece of work.”

Artwork ‘A thing of beauty. Destroy it forever’
by Richard DiCarlo | Derby

During times like these it’s often fun to revisit something familiar and approach things with a different slant. I have been taking some Pop culture and Art masterpieces and applying the vintage 1960’s and 70’s classic figures (Fisher Price, little people) to the make an amusing pieces. Here is my homage to Fisher -Price, Yellow […]

Twitter Feed
A Twitter List by CTMirror

Engage

  • Reflections Tickets & Sponsorships
  • Events
  • Donate
  • Newsletter Sign-Up
  • Submit to Viewpoints
  • Submit to ArtPoints
  • Economic Indicator Dashboard
  • Speaking Engagements
  • Commenting Guidelines
  • Legal Notices
  • Contact Us

About

  • About CT Mirror
  • Announcements
  • Board
  • Staff
  • Sponsors and Funders
  • Donors
  • Friends of CT Mirror
  • History
  • Financial
  • Policies
  • Strategic Plan

Opportunity

  • Advertising and Sponsorship
  • Speaking Engagements
  • Use of Photography
  • Work for Us

Go Deeper

  • Steady Habits Podcast
  • Economic Indicator Dashboard
  • Five Things

The Connecticut News Project, Inc. 1049 Asylum Avenue, Hartford, CT 06105. Phone: 860-218-6380

© Copyright 2021, The Connecticut News Project. All Rights Reserved. Website by Web Publisher PRO